Metastasis accounts for 90% of all human cancer related deaths, yet we lack adequate drugs to target this biological process often associated with aggressive cancers.^[@ref1]^ Accumulating evidence suggests an important role for matrix metalloproteinases (MMPs) in promoting cancer progression whereby they modify their surrounding environment to promote the growth and spread of tumor cells.^[@ref2]−[@ref5]^ Although MMPs represent the most prominent family of proteinases associated with tumorigenesis, drugs designed to inhibit their proteolytic activities largely failed in clinical trials due to issues with selectivity for individual MMPs.^[@ref6]^ The highly conserved catalytic domain within this family of zymogens required a paradigm shift to the development of novel MMP inhibitors (MMPIs) targeting less conserved, noncatalytic functional domain(s) of the proteases to increase target specificity and selectivity.^[@ref7]^

The biological functions of MMPs extend beyond just their proteolytic function and include induction of complex signaling cascades.^[@ref8]−[@ref10]^ Homodimerization of secreted proMMP-9 hemopexin domains is sufficient to induce cancer cell migration independent of proteolytic activity.^[@ref11]^ Using an shRNA approach, the mechanism behind this phenotype was dissected and found to be dependent on an interaction between MMP-9 and CD44 at the cell surface. This interaction required an intact MMP-9 hemopexin domain (PEX-9). Interaction between CD44 and PEX-9 results in increased epidermal growth factor receptor (EGFR) phosphorylation and subsequent activation of mitogen-activated protein kinase (MAPK)/extracellular signal--regulated kinases (ERK) signaling, thereby enhancing the migratory capacity of proMMP-9 expressing cancer cells.^[@ref12]^ Signaling was lost upon deletion or swapping of PEX-9 with the PEX domain of its closest homologue MMP-2.

The X-ray crystal structure of the PEX domain of MMP-9 has been solved. PEX-9 forms a propeller-like structure composed of four blades, which converge and are linked between blades I and IV through disulfide bonds.^[@ref13]^ Each blade of the PEX domain is composed of a single α-helix and four antiparallel β-strands. They form a scaffold for substrate recognition and docking^[@ref14]^

Published reports have shown that PEX-9 can interact with different integrin subunits to promote enhanced cancer cell migration, invasion, and survival in various cancer cell types.^[@ref15]−[@ref20]^ Of particular interest to our study was a recent finding that peptide sequence FPGVPLDTHDVFQYREKAYFC within the central cavity of PEX9/blade IV is a binding site for α4β1 integrin. Treatment with synthetic peptide was found to prevent B-cell chronic lymphocytic leukemia transendothelial cell migration and survival.^[@ref21],[@ref22]^ Mutation of either aspartic acid (Asp) residue (Asp-660 and Asp-663) in this peptide sequence abolished inhibition supporting the importance of Asp residues as key recognition sites for integrins.^[@ref23],[@ref24]^ Furthermore, the LDT motif in this peptide sequence is a highly conserved motif found in a variety of well-known α4β1 integrin ligands.^[@ref23],[@ref25],[@ref26]^

We previously utilized an *in silico* DOCKing approach for finding small molecules that bind to MMP-9 and identified a substituted pyrimidone, **1a**, which docked to the noncatalytic PEX domain of MMP-9.^[@ref27]^ Compound **1a** inhibited proMMP-9-mediated cancer cell migration and proliferation *in vitro*. Importantly, this compound did not inhibit MMP-9 enzymatic activity. Pyrimidone **1a** specifically binds to the hemopexin domain of MMP-9 and does not bind to closely related MMPs. In addition to inhibiting proMMP9-mediated cell migration, compound **1a** effectively prevented cancer metastasis in an *in vivo* mouse xenograft model.^[@ref27]^

In this current study, we generated an *in silico* library of analogs of compound **1a** to find a more potent compound for potential clinical application. After screening for optimal DOCKing scores *in silico*, the top 14 compounds were synthesized and tested in a 2-D collagen dot migration assay. A high nanomolar inhibitor that maintained MMP specificity was identified (compound **3c**). Our data demonstrate that PEX-9 inhibitor **3c** selectively inhibits cell migration induced by proMMP-9, leading to reduced cell invasion predominately through disruption of α4β1 integrin focal adhesion complexes. Thus, PEX-9 inhibitors rectify the abnormal migratory phenotype associated with high MMP-9 expression.

Results {#sec2}
=======

Development of a Second Generation Hit Compound {#sec2.1}
-----------------------------------------------

We designed analogs of compound **1a** based on possible derivative syntheses that utilized an amide and a thioether coupling. Thus, three moieties were varied: the amine (R^1^), the linker (\[CH~2~\]~*n*~), and the sulfhydrylpyrimidone (R^2^; [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). To rationally prioritize the synthesis of compound **1a** analogs, the University of California San Francisco (UCSF) DOCK (6.7) algorithm was used to rank various structures for predicted binding affinity. The proposed inhibitors were DOCKed to the PEX-9 domain pocket (PDB code 1ITV; [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A and B). This pocket is at the center of the four blades of the hemopexin domain.

![Synthesis of Inhibitors\
*Reagents and conditions*. (i) 2-Bromoacetic acid, EDC·HCl, DCM, room temp., 24 h: 67% for **6a**, 47% for **6c**, 28% for **6b**. (ii) NaOH, H~2~O, THF, 70 °C, 2 h: 63% for **1a**, 35% for **1b**, and 69% for **1c**. (iii) Ethyl 2-bromoacetate, K~2~CO~3~, MeOH, H~2~O, rt, 15 min, 67%. (iv) LiOH, MeOH, H~2~O, rt, 2 days, 28% for **8**, 66% for **9**. (v, a) EDC·HCl, DMAP, room temp., 24 h: 40% for **1d**, 41% for **2a**, 39% for **2c**, 52% for **3a**, 46% for **3b**, 70% for **3c**, 22% for **3d**, 36% for **4b**, 46% for **4c**, 42% for **4a**, 26% for **4d**; (b) CDI, room temp., 24 h, 45% for **4e**. (vi) Methyl 4-bromobutanoate, K~2~CO~3~, MeOH, H~2~O, reflux: 47% for **9** (overnight), 73% for **12** (overnight), 81% for **14** (1 h). (vii) Thiourea, MeONa, MeOH, reflux, overnight, 93%. (viii) NaOH, EtOH, RT, overnight, 99%. (ix) LiOH, DMSO, H~2~O, room temp., 2 h, 86%.](cb-2017-00758k_0007){#sch1}

![PEX-9 inhibitor DOCKing to PEX-9 and binding site analysis. (A,B) PEX-9 inhibitor derivatives were DOCKed within the central cavity of the hemopexin domain of PEX-9 MMP-9, and hydrogen bonding was visualized with dashed red lines. (C) A cluster of top hit compounds (**2c**, **3b**, **3c**, **3a**, **4a**, **4d**) was found to share a similar binding orientation. (D) The binding orientation of compound **1a** (green) relative to compound **3c** (red).](cb-2017-00758k_0001){#fig1}

Among a library of 66 analogs, 14 (compounds **1a**--**1d**, **2a**, **2c**, **3a**--**3d**, **4a**--**4e**) were chosen for synthesis based on superior DOCK algorithm scores ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, [Table S1](http://pubs.acs.org/doi/suppl/10.1021/acschembio.7b00758/suppl_file/cb7b00758_si_001.pdf)). One motif that demonstrated consistent improvement in predicted binding affinity was modification of the 6-propylpyrimidone group to bicyclic pyrimidone systems.

Chemical Synthesis of PEX-9 Parental Compound **1a** and Analogs {#sec2.2}
----------------------------------------------------------------

First, the early lead compound **1a** was resynthesized to confirm the chemical structure based on full characterization, using the synthetic route shown in the [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. The synthesis commenced with the reaction of aniline **5a** with bromoacetic acid in the presence of EDC·HCl to afford bromoacetanilide **6a** as a white solid in 67% yield. Subsequently, **6a** was reacted with thiouracil **7** in aqueous NaOH and heated to 70 °C for 48 h to give compound **1a** in 63% yield as a white solid after recrystallization. In addition, newly designed compounds **1b** and **1c** were synthesized using the same synthetic process ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

Closely related compound **1d** bearing a benzimidazole group was synthesized using a different route. In this synthesis, thiouracil **7** was converted to the corresponding thioacetic acid **8**, followed by the amide coupling with 2-aminobenzimidazole to give compound **1d** in modest yield. The attempted preparation of 2-bromoacetylaminobenzimidazole, following the synthetic route for compound **1a** did not yield a pure compound. Thus, we judged that the synthetic strategy which coupled R^1^ last would enable a better modular synthesis of analogs.

With this modular synthesis protocol in hand, we undertook synthesis of the analogs based on the original R^1^ moiety and two bicyclic sulfhydrylpyrimidones, as well as the linkers with different lengths and a variety of aromatic R^2^ substituents. Synthesis of compounds **2a** and **2c** followed the same strategy as that for compound **1d** by converting **7** to the corresponding thiobutanoic acid **9**, followed by amide formation by coupling with 4-substituted anilines **5a** and **5c** to give **2a** and **2c** in modest yields.

In a similar manner, compounds **3a**--**3d** were synthesized in moderate yields through the coupling of anilines and 2-aminobenzimidazole with thiobutanoic acid **12**, prepared from 2-sulfhydryl-5,6,7,8-tetrahydroquinazolin-4(3H)-one (**11**) as shown. Compound **11** was readily prepared by reacting keto ester **10** with thiourea and a base. Compounds **4a**--**4e** were synthesized in moderate yields using the same strategy except for starting from 2-sulfhydryltetrahydroquinazolinone (**13**) and employed anilines and 2-aminoimidazole for the amide formation.

Structure--Activity Relationship Analysis of PEX-9 Derivative Compounds {#sec2.3}
-----------------------------------------------------------------------

COS-1 cells were chosen for this set of experiments due to their low migratory capacity and complete lack of MMP-9 expression, thereby minimizing potential artifacts when interpreting the data. Overexpression of proMMP-9 results in enhanced cell migration in a two-dimensional dot migration assay.^[@ref27]^ This assay was initially used to test the efficacy of analogs at a single concentration, 50 μM. This concentration was used as a maximal cutoff because concentrations above 50 μM compound **1a** did not increase inhibitor effectiveness in COS-1 cells.

Cells were mixed with type I collagen solution with or without the compound, dotted onto a 96-well plate, and allowed to migrate for 18 h. They were then fixed, stained, and scored for the extent of migration ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A and B). 2-(4-Oxo-6-propyl-1,4-dihydropyrimidin-2-ylthio)-*N*(methyl)-phenylacetamide (**1f**) was used as a negative control.^[@ref27]^ Compound **3c** was the most effective and was selected for further study. The migration assay was repeated in HT1080 fibrosarcoma cells, which endogenously express MMP-9, and the same inhibition potency was observed for both compound **1a** and **3c** relative to control groups ([Supporting Information Figure 1A and B](http://pubs.acs.org/doi/suppl/10.1021/acschembio.7b00758/suppl_file/cb7b00758_si_001.pdf)).

![Structure--activity relationship analysis of all synthesized PEX-9 inhibitor derivatives. (A) Representative 20× magnification DAPI images of COS-1 cells engineered to stably express either vector control or proMMP-9 cDNA vectors in a two-dimensional migration assay after treatment with 50 μM of **1f**, **1a**, or **3c**. Scale bar = 250 μm. (B) Quantitative analysis of migrated COS-1 vector control and proMMP-9 expressing cells after treatment with 50 μM of inhibitors. (C) Tryptophan fluorescence emission of proMMP-9 or proMMP-9/PEX2 (ex, 280 nm; em, 330 nm) was monitored and inhibitor **3c** titrated into the protein solution. A maximal λ~Max~ shift of 9 nm was observed after treatment with 25 μM inhibitor. A solid line is a curve fit for *K*~d~ for compound **3c** that was determined. (D) *K*~d~ for each inhibitor was plotted against percent inhibition of proMMP9-mediated cell migration for each inhibitor.](cb-2017-00758k_0002){#fig2}

Compound Affinity for PEX-9 Binding {#sec2.4}
-----------------------------------

A blue shift in proMMP-9 tryptophan fluorescence was monitored to determine the binding affinity of all derivative compounds as previously described.^[@ref27]^ The *K*~d~ for compound **3c** binding to proMMP-9 is 0.32 μM ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C), four times tighter than parent compound **1a**. Moreover, a clear correlation between binding affinity and inhibition potency in the migration assay was observed ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}D). Thus, the biophysical SAR is maintained in the cellular assay, and increased inhibition of cell migration is MMP9-dependent and due to optimization of the chemical structure for binding the PEX-9 domain.

PEX-9 Binding Specificity {#sec2.5}
-------------------------

A chimera of proMMP-9 and MMP-2 in which the MMP-9 PEX domain was replaced by that of MMP-2 (proMMP-9/MMP-2PEX)^[@ref11]^ was tested for analog binding. The tryptophans in the MMP-9 PEX domain are conserved in the MMP-2 PEX domain. Upon titration of compound **3c** with the chimera, no shift in fluorescence was observed suggesting that **3c** does not bind to MMP2-PEX ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C).

As an additional test of binding selectivity, saturated transfer difference (STD) NMR was performed with purified recombinant proMMP-2 and proMMP-9 protein. ProMMP-2 and proMMP-9 are highly similar in structure and function, belonging to the same subfamily of MMPs known as the type IV collagenases and/or gelatinases. Thus, proMMP-2 constitutes the best control for testing the selectivity of the PEX-9 inhibitor.^[@ref28]^ Selective saturation of the 1.12 ppm resonance (proMMP-2 and proMMP-9) was used for STD NMR spectra. STD peaks were observed in the presence of proMMP-9, but not in the presence of proMMP-2, indicating that derivative compound **3c** is specific for the PEX-9 target ([Supplemental Figure 2A--F](http://pubs.acs.org/doi/suppl/10.1021/acschembio.7b00758/suppl_file/cb7b00758_si_001.pdf)). Thus, binding specificity is maintained upon increasing binding affinity.

PEX-9 Inhibitor Target Specificity {#sec2.6}
----------------------------------

To test whether compound **3c** is specific for inhibiting only proMMP9-mediated migration, a two-dimensional dot migration assay was performed using COS-1 cells engineered to stably express vector control pQCXIP, proMMP-2, proMMP-9, or proMMP-14 cDNA vectors ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A). An immunoblot was performed to confirm protein expression and proper localization of each MMP (MMP-2/-9 are secreted while MMP-14 is membrane bound; [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B). As expected, expression of these three MMPs resulted in enhanced cellular migration in COS-1 cells.^[@ref11]^ Treatment with either compound **1a** or **3c** only inhibited proMMP9-mediated migration: compound **3c** was significantly more effective at inhibiting migration ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C).

![Determination of PEX-9 inhibitor specificity in the presence of homologous and nonhomologous MMPs. (A) COS-1 cells transiently transfected with either vector control, proMMP-2, proMMP-9, or MMP-14 cDNAs were treated with 50 μM compound **3c** and then used in a two-dimensional dot migration assay. Representative 10× DAPI magnification images were taken and are shown. Scale bar = 250 μm. (B) MMP expression and proper localization was confirmed by immunoblot analysis of cell lysates and protein precipitated serum-free medium. pQCXIP is the vector only control. (C) Quantification of inhibition proMMP-9 mediated cell migration by compounds **1a** and **3c**. Compound **1f** was used as a negative control. (D) Assay of MMP-9 catalytic activity using a fluorogenic peptide degradation assay and activated MMP-9. proMMP-9 protein was activated with 1 mM APMA overnight. A total of 100 ng of activated MMP-9 was incubated with 10 μM fluorogenic peptide (excitation, 320 nm; emission, 405 nm) in the presence of buffer; 50 μM compound **1a**, **3c**, or **1f**; or 250 nM broad-spectrum catalytic inhibitor Marimastat. Readings were performed every 10 min over the course of 2 h. (E) Cell viability was assayed with MTT. COS-1 cells engineered to stably express either vector control or proMMP-9 cDNA were treated for 24 h with DMSO control, 50 μM compound **3c**, or 100 nM staurosporine (STS) as a positive control for acute cell toxicity.](cb-2017-00758k_0003){#fig3}

Effect of PEX-9 Inhibitor on MMP-9 Catalytic Activity {#sec2.7}
-----------------------------------------------------

Recombinant proMMP-9 protein was purified and incubated overnight in a 37 °C water bath in TNC buffer + 1 mM APMA to artificially activate the protein.^[@ref29],[@ref30]^ The next day, the purified protein was incubated with 10 μM fluorogenic peptide (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2), and catalytic activity was monitored over 2 h in the presence of compounds **1a**, **3c**, **1f**, and marimastat, a broad-spectrum MMP catalytic inhibitor. No inhibition of the catalytic activity was observed with **1a** or **3c**, corroborating that PEX-9 inhibitors do not modulate the catalytic activity of the protease. In the presence of marimastat (*K*~d~ = 80 nM), no substrate cleavage was observed ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}D). Therefore, inhibition of proMMP9-mediated cell migration by compound **1a** or **3c** is not due to a loss of proteolytic activity.

Cell Viability Analysis {#sec2.8}
-----------------------

Compound **3c** was evaluated for acute cytotoxicity. COS-1 cells stably expressing either vector control or proMMP-9 cDNA were treated with 50 μM **3c** for 24 h. As negative and positive controls, cells were treated with DMSO alone or 100 nM staurosporine (STS), an apoptosis inducer, respectively.^[@ref31]^ Significant cell death was only observed after treatment with STS. A nonstatistically significant 8% decrease in cell growth occurred after treatment with 50 μM of compound **3c** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}E). These experiments were repeated in endogenous MMP-9 expressing HT1080 fibrosarcoma cells, which were analyzed for chronic toxicity (cells were retreated every 3 days for a total of 9 days). No cell death was observed at 100 μM **3c** (data not shown).

PEX-9 Inhibitors Decrease MMP-9 Dimer Formation and Association with EGFR {#sec2.9}
-------------------------------------------------------------------------

Human fibroscarcoma HT1080 cells were cotransfected with MMP-9 cDNAs tagged with either a Myc or HA tag as previously reported.^[@ref12]^ The next day, cells were switched to serum free media and treated with 50 μM of either compound **1a** or **3c** overnight. Using the Myc antibody for immunoprecipitation and HA antibody for immunoblotting, the formation of dimeric MMP-9 was monitored. Compound **3c** significantly blocked MMP-9 dimer formation as compared to control compound **1f**. In addition, inhibition of PEX-9 with **1a** or **3c** reduced endogenous CD44 and EGFR coimmunoprecipitation ([Supporting Information Figure 3A](http://pubs.acs.org/doi/suppl/10.1021/acschembio.7b00758/suppl_file/cb7b00758_si_001.pdf)). Moreover, these PEX-9 inhibitors reduced phosphorylation of EGFR^Tyr1068^ and its downstream targets AKT^Ser473^ and Erk1/2^Thr202/Tyr204^ ([Supporting Information Figure 3B](http://pubs.acs.org/doi/suppl/10.1021/acschembio.7b00758/suppl_file/cb7b00758_si_001.pdf)).

PEX-9 Inhibitors Disrupt MMP-9 Interaction with α4β1 Integrin {#sec2.10}
-------------------------------------------------------------

HT1080 cells transiently cotransfected with tagged MMP-9 cDNAs were prepared as described above.^[@ref12]^ Inhibition of PEX-9 with 50 μM of either compound **1a** or **3c** reduced endogenous α4β1 integrin coimmunoprecipitation ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A). Inhibition of PEX-9 with 50 μM of either compound **1a** or **3c** reduced Src^Tyr418^ phosphorylation in addition to phosphorylation of Src downstream targets FAK^Tyr 576/577^ and PAX^Tyr118^ ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B).

![Treatment with PEX-9 inhibitor resulting in decreased interaction between MMP-9 and α4β1 integrin and attenuated downstream signaling. (A) Co-IP with HT1080 cells transiently overexpressing MMP-9/MYC cDNA was performed in the presence of 50 μM compound **3c**. MMP-9/MYC was immunoprecipitated using an anti-Myc antibody and served as an input control while α4 and β1 integrin interactions were probed *via* immunoblot. A decrease in MMP-9 interacting with both integrin subunits was observed as well as a (B) decrease in Src^Tyr418^ and downstream target proteins FAK^Tyr 576/577^/PAX^Tyr118^ phosphorylation. (C) 60× confocal images were captured, and representative images of MMP-9 (green) and each integrin subunit (red) were taken after treatment of HT1080 cells with 50 μM of either compound **1a**, **3c**, or **1f**. Scale bar = 100 μm. (D) 60× confocal images were captured, and representative images of p-FAK^Tyr 576/577^ (red) and p-PAX^Tyr118^ (green) were taken after treatment of HT1080 cells with 50 μM of either compound **1a**, **3c**, or **1f**. Scale bar = 100 μm.](cb-2017-00758k_0004){#fig4}

Evaluation of MMP-9 Cell Surface Localization upon Treatment with PEX-9 Inhibitors {#sec2.11}
----------------------------------------------------------------------------------

HT1080 cells were fixed in 4% paraformaldehyde then subsequently incubated with anti-MMP-9 in addition to anti-α4 and/or β1 integrin antibodies to monitor relative levels of localization of these proteins at the cell surface. The cells were counterstained with DAPI nuclear dye. Treatment with either compound **1a** or **3c** resulted in a loss of MMP-9 from the cell surface ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C). However, treatment with either solvent control DMSO or negative control compound **1f** did not disrupt the localization of MMP-9 on the cell surface.

Evaluation of Focal Adhesion Complexes in the Presence of PEX-9 Inhibitors {#sec2.12}
--------------------------------------------------------------------------

HT1080 cells were fixed after overnight treatment with 50 μM PEX-9 inhibitors, probed for either FAK^Tyr 576/577^ or PAX^Tyr118^ and counterstained with DAPI. A decrease in the formation of FAK and PAX adhesion junctions, normally depicted as "large punctae," was observed in cells after treatment with PEX-9 inhibitor compound **1a** or **3c** ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}D).

Validation of MMP-9's Role in Signaling {#sec2.13}
---------------------------------------

MMP-9 expression was silenced using an shRNA approach as previously described.^[@ref12]^ HT1080 cell lysates were collected and analyzed by immunoblot. Attenuation of MMP-9 expression resulted in a decrease in the phosphorylation of EGFR^Tyr1068^, FAK^Tyr 576/577^, PAX^Tyr118^, Src^Tyr418^, AKT^Ser473^, and Erk1/2^Thr202/Tyr204^ ([Supporting Information Figure 4A](http://pubs.acs.org/doi/suppl/10.1021/acschembio.7b00758/suppl_file/cb7b00758_si_001.pdf)). These findings are corroborated by Kinexus antibody microarray screening of phosphorylation-dependent signaling pathways in MMP-9-transfected COS-1 cells^[@ref12]^ in which Src, FAK, and PAX phosphorylation increase in proMMP-9 overexpressing cells ([Supporting Information Figure 4B](http://pubs.acs.org/doi/suppl/10.1021/acschembio.7b00758/suppl_file/cb7b00758_si_001.pdf)).

Treatment with PEX-9 Inhibitor Prevents Association of EGFR with CD44 and β1 Integrin {#sec2.14}
-------------------------------------------------------------------------------------

HT1080 cells were treated with 50 μM **3c**, **1a**, **1f**, or DMSO alone. Cell lysates were collected and analyzed by a co-IP assay in which endogenous EGFR was captured with an anti-EGFR antibody and served as an input control. CD44 and β1 integrin were individually probed on the immunoblot. Decreased interaction between EGFR-CD44 and EGFR-β1 integrin was observed after treatment with **3c** ([Supporting Information Figure 5A](http://pubs.acs.org/doi/suppl/10.1021/acschembio.7b00758/suppl_file/cb7b00758_si_001.pdf)).

Src Activation is a PEX-9 Dependent Process {#sec2.15}
-------------------------------------------

Non-MMP-9 expressing MCF-7 breast cancer cells were transiently transfected with either vector control pcDNA3.1, proMMP-9, or chimeric proMMP-9/MMP-2PEX cDNA constructs. Phosphorylation of Src^Tyr418^ was detected using an immunoblotting assay. Increased Src^Tyr418^ phosphorylation was observed in proMMP-9 overexpressing cells. PEX domain swapping with MMP-2 has no effect on Src^Tyr418^ phosphorylation, similar to vector control pcDNA3.1 expressing cells ([Supporting Information Figure 5B](http://pubs.acs.org/doi/suppl/10.1021/acschembio.7b00758/suppl_file/cb7b00758_si_001.pdf)).

Effect of PEX-9 Inhibitors on Cell Adhesion {#sec2.16}
-------------------------------------------

A 96-well plate was coated with a thin layer of either collagen or fibronectin (5 μg/mL in PBS) substrate before use. HT1080 cells were then seeded onto wells and incubated at 37 °C for 30 min in the presence of various inhibitors. Wells were washed and cells were fixed in 4% paraformaldehyde and stained with DAPI. Images of each 96-well plate were microscopically captured and counted for the number of cells still adherent to the coated surface using automated computer software. Compound **1a** or **3c** inhibited cellular adhesion, whereas treatment with Marimastat, a broad-spectrum MMP catalytic inhibitor, had no observable effect on cell attachment. Solvent DMSO and compound **1f** also had no effect on cell adhesion ([Supporting Information Figure 6A](http://pubs.acs.org/doi/suppl/10.1021/acschembio.7b00758/suppl_file/cb7b00758_si_001.pdf)).

Effect of Broad-Spectrum MMP Catalytic Inhibitor Marimastat on Focal Adhesion Complexes {#sec2.17}
---------------------------------------------------------------------------------------

HT1080 cells treated with 80 nM of broad-spectrum MMP inhibitor marimastat were analyzed by immunofluorescence microscopy for both p-FAK^Tyr 576/577^ and p-PAX^Tyr118^. Treatment with marimastat did not prevent the formation of focal adhesion contact sites in HT1080 cells ([Supporting Information Figure 6B](http://pubs.acs.org/doi/suppl/10.1021/acschembio.7b00758/suppl_file/cb7b00758_si_001.pdf)).

Treatment with PEX-9 Inhibitor Prevents Both Angiogenesis and Invasion in a Chorioallantoic Membrane (CAM) Assay {#sec2.18}
----------------------------------------------------------------------------------------------------------------

A CAM assay was carried out to evaluate angiogenic and invasive potential of HT1080 cells after treatment with **3c**. HT1080 cells were adsorbed onto a gelatin sponge and implanted onto the surface of the chicken embryo CAM followed by treatment with a 100 μM stock solution of compound **1f**, **1a**, or **3c** (final drug concentration is estimated to be 0.5 μM). After a 4-day incubation, neovascularization was imaged and quantified. Treatment with either compound **1a** or **3c** significantly reduced the angiogenic potential of HT1080 cells as compared to solvent DMSO and negative compound **1f** control treated cells ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A,B).

![Compound **3c** prevents angiogenesis and invasion through the basement membrane in a CAM assay. (A) HT1080 cells were adsorbed onto a gelatin sponge, implanted atop the CAM, and then subsequently treated with DMSO control or 0.5 μM compound **1f**, **1a**, or **3c**. After 4 days of incubation at 37 °C, representative images of the angiogenic bed surrounding the gelatin sponge were taken. (B) Analysis and quantification of the number of blood vessels in the area surrounding the implanted sponge. (C, D) The CAM was inoculated with HT1080 GFP^+^ cells mixed with a type I collagen solution and treated with DMSO control and 0.5 μM compound **1f**, **1a**, or **3c**. After 7 days of incubation at 37 °C, CAM membranes were isolated, sectioned, H&E stained, and imaged under 20× magnification.](cb-2017-00758k_0005){#fig5}

HT1080 cells stably expressing GFP were mixed with a type I collagen solution (3 mg mL^--1^) and seeded atop the CAM to ensure the cells localized to a specific area. Then, they were treated with a 100 μM stock solution of compound **1f**, **1a**, or **3c** (final drug concentration is estimated to be 0.5 μM). The invasion of cancer cells through the epithelium and basement membrane of the upper CAM into connecting tissue was examined by hematoxylin and eosin staining ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}C) in addition to fluorescence microscopy for GFP^+^ cells ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}D). Treatment of HT1080 cells with either compound **1a** or **3c** reduced invasion of CAM tissue compared to treatment with either DMSO or compound **1f** control.

Discussion {#sec3}
==========

MMPs are crucial for the degradation of ECM and blood vessel linings. Degradation allows tumor cells to escape their primary location and enter the circulatory system where they can travel to seed secondary tumors elsewhere in the body.^[@ref32],[@ref33]^ Therefore, targeting MMPs with inhibitors is of interest for cancer drug development.^[@ref34]^ Original inhibition attempts focused on synthetic collagen-mimicking hydroxamate inhibitors that chelate the zinc ion in the active site upon binding.^[@ref35]^ These drugs largely failed in clinical trials due to lack of selectivity for individual MMPs. Due to the specificity issues inherent in generating inhibitors of MMP proteolytic activity, we developed inhibitors which target MMP-9's hemopexin domain. MMP hemopexin domains share a common tertiary structure, yet the surface residues of MMP hemopexin domains are distinct, and one hemopexin domain cannot functionally substitute for another.

Identification of a More Potent PEX-9 Inhibitor {#sec3.1}
-----------------------------------------------

To identify compounds that bind more tightly to the hemopexin domain of MMP-9 than our original hit,^[@ref27]^ structural diversity was introduced at three positions and computational DOCKing utilized to prioritize synthesis and testing of a small subset. The similarities between their predicted and measured binding affinities indicate that the DOCKed structures may be used to infer important binding modalities. Compounds that displayed the greatest inhibition of proMMP-9 mediated migration had longer linkers with three methylenes between the amide and the sulfide moieties and at least one fluorine in the R^1^ group. A cluster of derivative compounds (**2c**, **3a**--**3c**, **4a**, **4d**) shared a similar binding geometry within the hemopexin domain of MMP-9 ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C). In all the tightest binding PEX-9 inhibitor derivatives, the aryl fluorine atoms were found deep within the binding pocket in contrast to the original hit **1a**, in which the difluoromethoxyphenol moiety remained solvent exposed. The STD-NMR data support the binding pose in which the aniline is deeply buried in the pocket ([Supporting Information Figure 2A--F](http://pubs.acs.org/doi/suppl/10.1021/acschembio.7b00758/suppl_file/cb7b00758_si_001.pdf)). In addition, fusion of a second ring to the pyrimidone moiety to form a quinazolinone significantly improved inhibitor efficiency and affinity. The length of the aliphatic chain between the two ring moieties is key for optimizing binding interactions. Comparison of DOCKed compounds **1a** and **3c** highlights differences in binding orientation that may contribute to the higher affinity of **3c** ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}D).

Binding affinity for PEX-9 correlates with inhibition of proMMP9-mediated migration ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}D) across our 16-compound series that spans 1.5 logs of binding affinity. These structure--activity results support the mechanism of inhibition of proMMP9-dependent cell migration being through targeting PEX-9 on the cell surface.

proMMP-9 homodimerization is a critical step for interaction with CD44 at the cell surface, which results in decreased phosphorylation of EGFR^Tyr1068^ and its downstream targets AKT^Ser473^ and Erk 1/2^Thr202/Tyr204^ phosphorylation.^[@ref12]^ Compound **3c** demonstrated enhanced efficacy of blocking proMMP-9 homodimerization and activation of downstream protein targets ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}, [Supporting Information Figure 3](http://pubs.acs.org/doi/suppl/10.1021/acschembio.7b00758/suppl_file/cb7b00758_si_001.pdf)). Moreover, our most potent compound, **3c**, retained specificity for a single MMP as demonstrated by the lack of inhibition in proMMP-2 or proMMP-14 mediated cell migration ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C). Our structure--activity correlation ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}D) and the specificity of inhibition for proMMP-9 mediated cell migration corroborate that compound **3c** targets PEX-9 *in vitro* and *in vivo* and not a downstream signaling target common to other mediators of cell migration.

Recently, Garcia-Pardo and co-workers reported that the central cavity of PEX-9 interacts with α4β1 integrin as a mechanism for cross-talk between MMPs and integrin focal adhesion formation.^[@ref17],[@ref18],[@ref21]^ In turn, Src kinase interacts with the cytoplasmic tail of α4β1 integrin subunits, which is critical for integrin function to promote and regulate focal adhesion turnover.^[@ref36]−[@ref42]^ Interestingly, PEX9-α4β1 integrin downstream signaling increases activation of Fyn, a Src family kinase, and drives chronic lymphocytic leukemia B cell survival.^[@ref17]^ Therefore, we examined the consequences of binding **3c** to PEX-9 on α4β1 integrin-mediated Src signaling.

Using a coimmunoprecipitation approach, we found that PEX-9 inhibitors interfere with binding between proMMP-9 and α4β1 integrin and can block cross-talk signaling. This disruption is accompanied by decreases in phosphorylation levels of Src^Tyr418^ and its downstream substrates FAK^Tyr 576/577^ and PAX^Tyr118^ ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B). Immunofluorescence imaging in HT1080 cells further supported the idea that focal adhesion junctions ("large punctae") were lost upon treatment with the PEX-9 inhibitor ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C,D). We also demonstrated that overexpression of proMMP-9 in MCF-7 breast cancer cells enhanced Src activation. Overexpression of proMMP-9/MMP2-PEX in MCF-7 breast cancer cells or silencing of endogenous MMP-9 expression in HT1080 attenuated Src activation. Taken together, the data suggest that the proMMP-9 hemopexin domain is required for enhanced cellular adhesion and migration.

Potential Mechanism by Which Src Is Activated {#sec3.2}
---------------------------------------------

Our data are in agreement with the literature showing that α4β1 integrin clustering is sufficient for activation of Src kinase.^[@ref37],[@ref43]^ However, in addition to integrin clustering, EGFR can directly activate Src kinase, and EGFR interacts with β1 integrin.^[@ref44]−[@ref46]^

It is proposed that proMMP-9 forms a large charged surface for complex interactions with multiple surface proteins involved in outside-in signaling.^[@ref47]^ The hemopexin domain of proMMP-9 may act as a scaffold to enhance clustering of α4β1 integrin-EGFR-CD44 at the cell surface and result in aberrant Src activation.^[@ref48]^ Garcia-Pardo and co-workers demonstrated that a peptide mimicking blade 1 of PEX-9 inhibits interaction with integrin and that a second peptide mimicking blade 4 of PEX-9 inhibits interaction with CD44.^[@ref21],[@ref22]^ We reasoned that our inhibitor, which binds directly to PEX-9, could simultaneously disrupt both interactions. Indeed, our coimmunoprecipitation experiments demonstrate that the addition of **3c** selectively disrupts proMMP-9 interaction with both α4β1 integrin ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}) and CD44 ([Supporting Information Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acschembio.7b00758/suppl_file/cb7b00758_si_001.pdf)).

Importantly, our inhibitor is specific for MMP-9. Targeting the hemopexin domain to investigate the role of MMP-9 in promoting cellular adhesion has identified a connection to integrin and Src in a complex adhesion network as depicted in [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}. There are currently no effective cancer therapeutics designed to target adhesion receptors because cancer cells can change the mechanism by which they migrate depending upon their environmental constraints.^[@ref49]^ Our *in vivo* CAM experiments demonstrate that we can inhibit two key determinants of tumor cell metastatic potential, angiogenesis and invasion ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}), through PEX domain targeting. Our small molecule inhibitor paves the way for designing new therapeutic strategies for the treatment of metastatic disease and opens the door for the future development of new technologies and tools for understanding the role of individual MMPs in cancer progression. Development of PEX inhibitors for other MMPs will provide understanding of their noncatalytic functions and a strategy for reducing undesirable off-target effects previously observed in broad-spectrum MMP catalytic inhibitor clinical trials.

![Overview of the mechanism by which MMP-9 regulates formation of focal adhesion junctions. (A) During exocytosis and upon being secreted into the extracellular space, proMMP-9 forms a large complex with itself that can then act as a scaffold for promoting outside-in signaling. In our model, PEX-9 scaffolding promotes the association of β1 integrin-EGFR-CD44. Interaction with CD44 results in enhanced EGFR activation in addition to increased phosphorylation of its downstream targets AKT and Erk 1 + 2 (through the MAPK/Erk pathway). While complexed to β1 integrin, EGFR then goes on to transactivate Src kinase after it is recruited to the α4 integrin subunit during the generation of a new focal adhesion contact site. After activation, Src can then directly phosphorylate FAK currently associated with the β1 integrin subunit resulting in its maximal catalytic activity. This active Src--FAK complex can then bind and activate PAX, resulting in a mature FAK-PAX complex necessary for the formation of focal adhesion junctions. Formation of a complex between FAK and PAX results in final translocation to ECM--integrin junctions at the cell surface where they regulate cytoskeletal interactions resulting in enhanced cellular adhesion, migration, and invasion of cancer cells. (B) Treatment with PEX-9 inhibitor (depicted as red triangle) prevents MMP-9 scaffolding, thereby preventing downstream signaling driven by EGFR activation.](cb-2017-00758k_0006){#fig6}

Experimental Methods {#sec4}
====================

Materials {#sec4.1}
---------

Collagen type I (acetic-acid-extracted native type I collagen from rat tail tendon) was obtained from BD Bioscience Discovery Labware (Franklin Lakes, NJ). Fibronectin solution was purchased from Sigma-Aldrich (St. Louis, MO). Hoechst nuclear stain was obtained from Invitrogen (Grand Island, NY). Rabbit anti-p-AKT^Ser473^, anti-AKT (total), anti-β1 integrin, anti-p-Erk1/2^Thr202/Tyr204^, anti-p-FAK^Tyr 576/577^, anti-FAK (total), anti-p-PAX^Tyr118^, anti-PAX (total), and anti-EGFR (total) antibodies were all purchased from Cell Signaling Technology (Danvers, MA). Mouse anti-Erk1/2 (total), anti-β-actin, and anti-α/β-tubulin antibodies were also purchased from Cell Signaling Technology (Danvers, MA). Rabbit anti-p-Src^Tyr418^ and anti-Src (total) in addition to mouse anti-β1 integrin were obtained from Abcam (Cambridge, MA). Mouse anti-α4 integrin and anti-CD44 in addition to rabbit anti-α4 integrin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-MMP-9 was purchased from Millipore (Darmstadt, Germany). Rabbit p-EGFR^Tyr1068^ was obtained from Enzo Life Sciences (Ann Arbor, MI). Rat anti-CD44 was obtained through BD Pharmingen (San Diego, CA). Mouse anti-HA was purchased from Invitrogen-ThermoFisher Scientific (Waltham, MA). Rabbit anti-MYC and anti-HA in addition to horseradish peroxidase conjugated antirabbit, antimouse, and antirat antibodies were obtained from Rockland Immunochemicals (Gilbertsville, PA). Mouse anti-MYC was purchased from Roche Life Sciences (Branford, CT). Alexa Fluor 488 and 568 antirabbit/-mouse antibodies were purchased from Molecular Probes, Life Technologies (Grand Island, NY). proMMP-9 used in kinetic experiments was purchased from Biolegends (San Diego, CA). Mca-PLGL-Dpa-AR-NH~2~ Fluorogenic MMP Peptide Substrate was purchased from R&D Systems (Minneapolis, MN). Chemicals were purchased from Sigma-Aldrich, Fisher Scientific, and VWR International and used as received or purified before use by standard methods. Tetrahydrofuran was freshly distilled from sodium and benzophenone. Dichloromethane was also distilled immediately prior to use under nitrogen from calcium hydride. 2-(4-Oxo-6-propyl-1,4-dihydropyrimidin-2-ylthio)-*N*(methyl)-phenylacetamide (**1f**) was purchased from ChemBridge Corp. (San Diego, CA).

General Methods {#sec4.2}
---------------

^1^H and ^13^C NMR spectra were measured on a Bruker 300, 400, 500, or 700 MHz spectrometer. Melting points were measured on a Thomas-Hoover capillary melting point apparatus and are uncorrected. TLC was performed on Sorbent Technologies aluminum-backed Silica G TLC plates (Sorbent Technologies, 200 μm, 20 cm × 20 cm), and column chromatography was carried out on silica gel 60 (Merck, 230--400 mesh ASTM). High-resolution mass spectrometry analysis was carried out on an Agilent LC--UV--TOF mass spectrometer at the Mass Spectrometry facility of the Institute of Chemical Biology and Drug Discovery, Stony Brook University.

Chemical Synthesis of PEX-9 Inhibitor Compounds and Characterization Data {#sec4.3}
-------------------------------------------------------------------------

### *N*-(4-Difluoromethoxyphenyl)-2-(4-oxo-6-propyl-1,4-dihydropyrimidin-2-ylthio)acetamide (**1a**) {#sec4.3.1}

To a solution of bromoacetic acid (170 mg, 1.25 mmol) and EDC·HCl (239 mg, 1.25 mmol) in dichloromethane (6 mL) was added aniline (**5a**, 200 mg, 1.25 mmol) and was stirred at RT overnight. After the completion of the reaction, the reaction mixture was diluted with dichloromethane and washed twice with 1 N hydrochloric acid, twice with a saturated solution of sodium bicarbonate and twice with brine. The organic layers were collected, dried over magnesium sulfate, filtered, and concentrated to afford an off-white crude product. The crude product was recrystallized from hexanes/dichloromethane to give bromoacetanilide **6a** as a white solid (227 mg, 65% yield). ^1^H NMR (300 MHz, CDCl3): δ 4.27 (s, 2 H), 6.30--6.79 (s, 1 H), 7.21 (d, 2 H, *J* = 9 Hz), 7.63 (d, 2 H, *J* = 9 Hz).

To a solution of sodium hydroxide (7.2 mg, 0.18 mmol) in water (2 mL) was added 2-hydrosulfanyl-4-oxo-6-propyl-1,4-dihydropyrimidine (**7**; 30 mg, 0.18 mmol), and the mixture was stirred until all of **1** was dissolved. To the mixture was added a solution of **6a** (50 mg, 0.18 mmol) in tetrahydrofuran (2 mL) and heated at 60 °C for 2 h and then at 70 °C overnight. After the completion of the reaction, a white precipitate was observed, which was collected on a filter and recrystallized from ethanol to afford **1a** as white solid (42 mg, 63% yield). Mp: 180 °C (decomp.). ^1^H NMR (700 MHz, DMSO-*d*~6~): δ 0.73 (t, *J* = 7.0 Hz, 3H), 1.51 (m, 2H), 2.32 (t, *J* = 7.0 Hz, 2H), 4.05 (s, 2H), 5.97 (s, 1H), 6.97--7.29 (m, 3H), 7.62 (d, *J* = 8.4 Hz, 2H), 10.44 (s, 1H). ^13^C NMR (175 MHz, DMSO-*d*~6~): δ 13.4, 20.6, 35.1, 38.2, 116.5.0 (t, *J* = 256.0 Hz), 119.5, 120.4, 136.4, 146.3, 165.9. ^19^F NMR (376 MHz, DMSO-*d*~6~): δ −81.6. HRMS (ESI+) calcd for C~16~H~18~F~2~N~3~O~3~S \[M + H\]^+^: 370.1031. Found: 370.1039 (Δ= −2.02 ppm).

In the same manner, **1b** and **1c** were synthesized.

### 2-(4-Oxo-6-propyl-1,4-dihydropyrimidin-2-ylthio)-*N*-phenylacetamide (**1b**) {#sec4.4.1}

White solid, 35% yield. Mp: 170 °C (decomposed). ^1^H NMR (700 MHz, DMSO-*d*~6~): δ 0.83 (t, *J* = 7.0 Hz, 3H), 1.46--1.56 (m, 2H), 2.31 (t, *J* = 7.0 Hz, 2H), 4.04 (s, 2H), 5.90 (s, 1H), 7.04 (t, *J* = 7.7 Hz, 1H), 7.30 (t, *J* = 7.7 Hz, 2H), 7.56 (t, *J* = 7.7 Hz, 2H), 10.33 (s, 1H), 12.67 (s, 1H). ^13^C NMR (175 MHz, DMSO-*d*~6~): δ 13.4, 20.5, 35.1, 38.5, 119.0, 123.3, 128.7, 139.0, 165.9. HRMS (ESI+) calcd for C~15~H~18~N~3~O~2~S \[M + H\]^+^: 304.1114. Found: 304.1113 (Δ= 0.29 ppm).

### *N*-(4-Fluorophenyl)-2-(4-oxo-6-propyl-1,4-dihydropyrimidin-2-ylthio)acetamide (**1c**) {#sec4.4.2}

White solid, 69% yield. Mp: 191--194 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 0.73 (t, *J* = 7.0 Hz, 3H), 1.45--1.56 (m, 2H), 2.31 (t, *J* = 7.0 Hz, 2H), 4.02 (s, 2H), 6.94 (s, 1H), 7.10--7.19 (m, 2H), 7.55--7.62 (m, 2H), 10.30 (s, 1H), 12.54 (s,1H). ^13^C NMR (500 MHz, DMSO-*d*~6~): δ 13.4, 20.5, 35.0, 38.5, 115.3 (d, *J* = 22.1 Hz), 120.7 (d, *J* = 7.7 Hz), 135.5 (d, *J* = 2.5 Hz), 158.0 (d, *J* = 238.4 Hz), 165.8. ^19^F NMR (376 MHz, DMSO-*d*~6~): δ −119.3. HRMS (ESI+) calcd for C~15~H~17~FN~3~O~2~S \[M + H\]^+^: 322.1020. Found: 322.1020 (Δ= −0.03 ppm).

### *N*-(1H-benzo\[d\]imidazol-2-yl)-2-(4-oxo-6-propyl-1,4-dihydropyrimidin-2-ylthio)acetamide (**1d**) {#sec4.4.3}

To a solution of thiouracil **7** (1.70 g, 10.0 mmol) and potassium carbonate (2.07 g, 15.0 mmol) in MeOH (10 mL) and water (20 mL) was added ethyl 2-bromoacetate (1.42 g, 8.5 mmol). The mixture was stirred at RT for 15 min and 50 mL water was added. Then, the reaction mixture was extracted with ethyl acetate (5 × 80 mL). The organic layers were combined and washed with water (100 mL) and brine (100 mL) and dried over MgSO~4~, and the solvent was removed by rotary evaporator. The crude product was purified by flash column chromatography on silica gel using MeOH/DCM as an eluent to give ethyl 2-(4-oxo-6-propyl-1,4-dihydropyrimidin-2-ylthio)acetate as a white solid (1.7 g, 67% yield). Mp: 117--118 °C. ^1^H NMR (300 MHz, CDCl~3~): δ 0.93 (t, *J* = 7.2 Hz, 3H), 1.27 (t, *J* = 7.2 Hz, 3H), 1.59--1.65 (m, 2H), 2.43 (t, *J* = 7.2 Hz, 2H), 3.93 (s, 2H), 4.20 (q, *J* = 7.2 Hz, 2H), 6.05 (s, 1H), 13.17 (s, 1H). ^13^C NMR (175 MHz, CDCl~3~): δ 13.6, 14.1, 20.8, 32.8, 39.5, 61.9, 108.2, 158.9, 165.5, 168.2, 169.2. HRMS (ESI+) calcd for C~11~H~17~N~2~O~3~S \[M + H\]^+^: 257.0954. Found: 257.0953 (Δ = 0.48 ppm).

To a solution of ethyl 2-((4-oxo-6-propyl-1,4-dihydropyrimidin-2-yl)thio)acetate (1.20 g, 4.68 mmol) in MeOH and water was added lithium hydroxide (0.2 g, 9.36 mmol). The mixture was stirred at RT for 2 days. The reaction mixture was adjusted to pH 1 by 1N hydrochloric acid and extracted with ethyl acetate (5 × 80 mL). The organic layers were combined and dried over MgSO~4~, and the solvent was removed by rotary evaporator to afford thioacetic acid **8** (0.30 g, 28%) as a white solid. Mp: 154--155 °C. ^1^H NMR (700 MHz, DMSO-*d*~6~): δ 0.86 (t, *J* = 7.0 Hz, 3H), 1.56 (m, 2H), 2.30 (t, *J* = 7.0 Hz, 2H), 3.47 (s, 2H), 5.79 (s, 1H). ^13^C NMR (175 MHz, DMSO-*d*~6~): δ 13.6, 20.7, 36.1, 38.2, 107.4, 163.7, 164.3, 166.3, 171.2. HRMS (ESI+) calcd for C~9~H~13~N~2~O~3~S \[M + H\]^+^: 229.0641. Found: 229.0644 (Δ = −1.11 ppm).

To a mixture of 2-(6-oxo-4-propyl-1,6-dihydropyrimidin-2-ylthio)acetic acid (**8**; 228 mg, 1.0 mmol), 1H-benzo\[d\]imidazol-2-amine (**5d**, 146 mg, 1.1 mmol), and DMAP (134 mg, 1.1 mmol) in DMF (3 mL) was added EDC·HCl (211 mg, 1.1 mmol), and the mixture was stirred at RT for 24 h. A total of 50 mL of water was added, and the resulting precipitate was filtered to give a solid, which was recrystallized from 1,4-dioxane to give compound **1d** (136 mg, 40%) as an off-white solid. Mp: 217 °C (decomposed). ^1^H NMR (700 MHz, DMSO-*d*~6~): δ 0.63 (t, *J* = 7.0 Hz, 3H), 1.50--1.40 (m, 2H), 2.27 (t, *J* = 7.0 Hz, 2H), 4.14 (s, 2H), 5.93 (s, 1H), 7.05--7.09 (m, 2H), 7.40--7.43 (m, 2H), 12.10 (s, 3H). ^13^C NMR (175 MHz, DMSO-*d*~6~): δ 13.3, 20.5, 34.5, 38.4, 106.5, 111.5, 114.1, 120.3, 121.0, 136.3, 146.7, 161.6, 162.3, 163.9, 167.7. HRMS (ESI+) calcd for C~16~H~18~N~5~O~2~S \[M + H\]^+^ 344.1176. Found: 344.118 (Δ= −1.1 ppm).

### *N*-(4-Difluoromethoxyphenyl)-4-(4-oxo-6-propyl-1,4-dihydropyrimidin-2-ylthio)butanamide (**2a**) {#sec4.4.4}

To a solution of thiouracil **7** (0.85 g, 5 mmol) and potassium carbonate (1.03g, 7.5 mmol) in methanol (5 mL) and water (10 mL) was added methyl 4-bromobutanoate (1.36g, 7.5 mmol). The solution was heated to reflux overnight. The reaction mixture was cooled to RT and 50 mL of water added, and the mixture was extracted with ethyl acetate (3 × 50 mL). The organic layers were combined and washed with water (50 mL) and brine (50 mL) and dried over MgSO~4~, the solvent was removed by rotary evaporator. The crude product was purified by flash column chromatography on silica gel using MeOH/DCM as an eluent to give methyl 4-(4-oxo-6-propyl-1,4-dihydropyrimidin-2-ylthio)butanoate as a white solid (0.64 g, 47% yield). Mp: 129--130 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 0.95 (t, *J* = 7.0 Hz, 3H), 1.64--1.71(m, 2H), 2.06 (m, 2H), 2.46 (m, 4H), 3.24 (t, *J* = 7.0 Hz, 2H), 3.68 (s, 3H), 6.04 (s, 1H), 12.99 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 13.8, 21.0, 24.7, 29.9, 32.7, 39.7, 51.8, 108.0, 160.2, 165.6, 169.5, 173.4. HRMS (ESI+) calcd for C~12~H~19~N~2~O~3~S \[M + H\]^+^: 271.1111. Found: 271.111 (Δ= 0.51 ppm).

To a solution of methyl 4-(4-oxo-6-propyl-1,4-dihydropyrimidin-2-ylthio)butanoate (500 mg, 1.84 mmol) in MeOH and water was added lithium hydroxide (88.1 mg, 3.68 mmol), and the mixture was stirred at RT for 2 days. The mixture was adjusted to pH 1 by 1N hydrochloric acid to form a white precipitate. The precipitate was collected on a filter to afford 4-(4-oxo-6-propyl-1,4-dihydropyrimidin-2-ylthio)butanoic acid **9** as a white solid (308.0 mg, 66% yield). Mp: 139--141 °C. ^1^H NMR (300 MHz, CDCl~3~): δ 0.95 (t, *J* = 7.3 Hz, 3H), 1.68 (m, 2H), 2.01--2.14(m, 2H), 2.49 (m, 4H), 3.28 (t, *J* = 6.5 Hz, 2H), 6.04 (s, 1H). ^13^C NMR (175 MHz, CDCl~3~): δ 13.8, 21.1, 24.5, 29.9, 32.8, 39.7, 107.7, 160.3, 165.9, 170.2, 178.5. HRMS (ESI+) calcd for C~11~H~17~N~2~O~3~S \[M + H\]^+^: 257.0954. Found: 257.0958 (Δ= −1.33 ppm).

To a mixture of **9** (190 mg, 0.74 mmol), 4-(difluoromethoxy)aniline (**5a**, 130.5 mg, 0.82 mmol), and 4-(dimethylamino)pyridine (DMAP; 99.4 mg, 0.81 mmol) in dimethylformamide (DMF; 3 mL) was added *N*′-ethylcarbodiimide hydrochloride (EDC·HCl (156 mg, 0.81 mmol)); the mixture was stirred at RT for 1 h. Then, 100 mL of water was added to the reaction mixture to form an off-white precipitate, which was collected on a filter to give an off-white solid. The solid was dissolved in ethyl acetate and dried over MgSO~4~ and filtered, and the solvent was removed by rotary evaporator. The crude product was purified by recrystallization from ethyl acetate/hexane to afford **2a** as a white solid (120.4 mg, 41% yield). Mp: 174--177 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 0.92 (t, *J* = 7.5 Hz, 3H), 1.64 (m, 2H), 2.06--2.22 (m, 2H), 2.42 (t, *J* = 7.5 Hz, 2H), 2.49 (t, *J* = 6.9 Hz, 2H), 3.31 (t, *J* = 5.7 Hz, 2H), 6.01 (s, 1H), 6.45 (t, *J* = 74.0 Hz, 1H), 7.07 (d, *J* = 8.6 Hz, 2H), 7.55 (d, *J* = 8.6 Hz, 2H), 7.92 (s, 1H), 12.69 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 13.8, 21.1, 24.8, 30.2, 35.5, 39.7, 107.8, 116.1 (t, *J* = 259 Hz), 120.6, 121.3, 135.6, 147.3, 160.2, 165.5, 169.9, 170.5. ^19^F NMR (376 MHz, CDCl~3~): δ −80.7. HRMS (ESI+) calcd for C~18~H~22~F~2~N~3~O~3~S \[M + H\]^+^: 398.1344. Found: 398.1345 (Δ = −0.03 ppm).

In the same manner, compound **2c** was synthesized.

### *N*-(4-Fluorophenyl)-4-(4-oxo-6-propyl-1,4-dihydropyrimidin-2-ylthio)butanamide (**2c**) {#sec4.5.1}

White solid, 39% yield. Mp: 180--182 °C. ^1^H NMR (300 MHz, CDCl~3~): δ 0.83--0.96 (t, *J* = 7.3 Hz, 3H), 1.57--1.69 (m, 2H), 2.05--2.21 (m, 2H), 2.33--2.55 (m, 4H), 3.31 (t, *J* = 6.3 Hz, 2H), 6.02 (s, 1H), 7.00 (t, *J* = 8.7 Hz, 2H), 7.49 (m, 2H), 7.64 (s, 1H), 12.45 (s, 1H). ^13^C NMR (175 MHz, DMSO-*d*~6~): δ 13.4, 20.5, 24.8, 29.2, 34.9, 38.5, 115.2 (d, *J* = 22.0 Hz), 120.7 (d, *J* = 7.7 Hz), 135.7 (d, *J* = 2.3 Hz), 157.1, 158.5, 170.3. ^19^F NMR (376 MHz, CDCl~3~): δ −119.7. HRMS (ESI+) calcd for C~17~H~21~FN~3~O~2~S \[M + H\]^+^: 350.1333. Found: 350.134 (Δ = −2.12 ppm).

### 4-(4-Oxo-3,4,5,6,7,8-hexahydroquinazolin-2-ylthio)-*N*-phenylbutanamide (**3b**) {#sec4.5.2}

Ethyl 2-oxocyclohexane-1-carboxylate 10 (1.70 g, 10.0 mmol) and thiourea (1.52 g, 20.0 mmol) were added to a sodium methoxide solution (0.58 g sodium in 20 mL methanol), and the mixture was refluxed overnight. The solvent was removed, and the residue was dissolved in hot water (50 mL). Glacial acetic acid (6 mL) was added dropwise to make the solution acidic until a white solid was formed. The precipitate was collected by a filter and washed successively with saturated sodium bicarbonate (3 × 10 mL) and water (3 × 10 mL) and recrystallized from ethyl acetate (30 mL) to afford 2-sulfhydryl-5,6,7,8-tetrahydroquinazolin-4(3H)-one (**11**; 1.70 g, 93%) as a white solid. Mp \> 230 °C. ^1^H NMR (700 MHz, DMSO-d6): δ 1.53--1.76 (m, 4H), 2.16 (t, *J* = 6.0 Hz, 2H), 2.36 (t, *J* = 6.0 Hz, 2H), 12.09 (s, 1H), 12.25 (s, 1 H). ^13^C NMR (175 MHz, DMSO-*d*~6~): δ 20.5, 20.7, 20.9, 25.5, 111.6, 149.5, 161.3, 173.9. HRMS (ESI+) calcd for C~8~H~11~N~2~OS \[M + H\]+: 183.0587. Found: 183.0587 (Δ = −0.44 ppm).

To a solution of **11** (1.59 g, 8.72 mmol) in anhydrous methanol (15 mL) was added methyl 4-bromobutanoate (1.72 g, 9.55 mmol) and potassium carbonate (1.31 g, 9.48 mmol). The reaction mixture was heated to reflux overnight. After being cooled to RT, the reaction mixture was concentrated *in vacuo* to remove the solvent. To the residue was added water (50 mL), and it was extracted with dichloromethane (4 × 40 mL). The combined organic phases were washed with brine (5 mL), dried over MgSO~4~, and concentrated *in vacuo* to give a crude product, which was purified by recrystallization from ethyl acetate to afford methyl 4-(4-oxo-3,4,5,6,7,8-hexahydroquinazolin-2-ylthio)butanoate (1.80 g, 73%) as a white solid. Mp: 149--150 °C. ^1^H NMR (700 MHz, CDCl~3~): δ 1.69--1.79 (m, 4H), 2.01--2.06 (m, 2H), 2.47 (m, 4H), 2.59 (t, *J* = 7.0 Hz, 2H), 3.22 (t, *J* = 7.0 Hz, 2H), 3.67 (s, 3H). ^13^C NMR (175 MHz, CDCl~3~): δ 21.7, 21.8, 22.2, 24.7, 29.8, 31.6, 32.7, 51.8, 117.6, 156.4, 162.0, 165.0, 173.5. HRMS (ESI+) calcd for C~13~H~19~N~2~O~3~S \[M + H\]^+^ 283.1111. Found: 283.1117 (Δ = −2.09 ppm).

To a mixture of 2N sodium hydroxide (1.51 g in 19 mL water) and ethanol (22 mL) was added methyl 4-(4-oxo-3,4,5,6,7,8-hexahydroquinazolin-2-ylthio)butanoate (1.34 g, 4.75 mmol) at RT. The mixture was stirred overnight at RT. The reaction mixture was adjusted to pH 5 with 1N hydrochloric acid and extracted with dichloromethane (5 × 40 mL). The combined organic phases were dried over MgSO~4~ and concentrated *in vacuo* to give a residue, which was recrystallized from dichloromethane to afford 4-(4-oxo-3,4,5,6,7,8-hexahydroquinazolin-2-ylthio)butanoic acid **12** (1.26 g, 99% yield) as a white solid. Mp: 176--177 °C. ^1^H NMR (700 MHz, CD~3~OD): δ 1.71--1.81 (m, 4H), 1.96--2.03 (m, 2H), 2.39 (t, *J* = 6.3 Hz, 2H), 2.43 (t, *J* = 7.0 Hz, 2H), 2.57 (t, *J* = 6.3 Hz, 2H), 3.23 (t, *J* = 7.0 Hz, 2H). ^13^C NMR (175 MHz, CD~3~OD): δ 22.7, 22.9, 23.1, 26.0, 30.4, 33.4, 176.6. HRMS (ESI+) calcd for C~12~H~17~N~2~O~3~S \[M + H\]^+^: 269.0954. Found: 269.0959 (Δ= −1.54 ppm).

To a mixture of thiobutanoic acid **12** (134 mg, 0.50 mmol), aniline **5b** (70 mg, 0.75 mmol), and DMAP (67 mg, 0.55 mmol) in DMF (2 mL) was added EDC·HCl (105 mg, 0.55 mmol), and the mixture was stirred at RT for 48 h. To the reaction mixture was added 50 mL of water with stirring to form a precipitate. The resulting precipitate was collected on a filter and recrystallized from ethyl acetate to give **3b** (79 mg, 46% yield) as an off-white solid. Mp: 193--194 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.56--1.67 (m, 4H), 1.91--1.97 (m, 2H), 2.26 (m, 2H), 2.39--2.45 (m, 4H), 3.16 (t, *J* = 7.0 Hz, 2H), 7.01 (t, *J* = 8.0 Hz, 1H), 7.27 (t, *J* = 8.0 Hz, 2H), 7.58 (d, *J* = 8.0 Hz, 2H), 9.90 (s, 1H), 12.42 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.4, 21.8, 24.7, 29.0, 31.1, 34.9, 119.0, 122.9, 128.6, 139.3, 170.3. HRMS (ESI+) Calcd for C~18~H~22~N~3~O~2~S \[M + H\]^+^: 344.1427. Found: 344.1430 (Δ = −0.71 ppm).

In the same manner, compounds **3a**, **3c**, and **3d** were synthesized.

### *N*-(4-Difluoromethoxyphenyl)-4-(4-oxo-3,4,5,6,7,8-hexahydroquinazolin-2-ylthio)butanamide (**3a**) {#sec4.6.1}

Off-white solid, 52% yield. Mp: 197--198 °C. ^1^H NMR (700 MHz, acetone-*d*~6~): δ 1.63--1.73 (m, 4H), 2.09 (m, 2H), 2.35 (t, *J* = 6.3 Hz, 2H), 2.47 (t, *J* = 6.3 Hz, 2H), 2.53 (t, *J* = 7.0 Hz, 2H), 3.27 (t, *J* = 7.0 Hz, 2H), 6.90 (t, *J* = 74.4 Hz, 1H), 7.11 (d, *J* = 8.4 Hz, 2H), 7.70 (d, *J* = 8.4 Hz, 2H), 9.27 (s, 1H), 11.46 (s, 1H). ^13^C NMR (175 MHz, acetone-*d*~6~): δ 22.4, 22.5, 23.0, 26.0, 32.2, 35.9, 117.6 (t, *J* = 255.5 Hz), 117.9, 120.6, 121.3, 137.9, 147.6 (t, *J* = 2.6 Hz), 157.2, 161.2, 163.4, 171.2. ^19^F NMR (376 MHz, acetone-*d*~6~): δ −82.3. HRMS (ESI+) Calcd for C~19~H~22~F~2~N~3~O~3~S\[M + H\]^+^: 410.1344. Found: 410.1346 (Δ = −0.33 ppm).

### *N*-(4-Fluorophenyl)-4-(4-oxo-3,4,5,6,7,8-hexahydroquinazolin-2-ylthio)butanamide (**3c**) {#sec4.6.2}

White solid, 70% yield. Mp: 211.5--213 °C. ^1^H NMR (700 MHz, DMSO-*d*~6~): δ 1.56--1.66 (m, 4H), 1.94 (m, 2H), 2.26 (t, *J* = 5.6 Hz, 2H), 2.41 (t, *J* = 7.0 Hz, 4H), 3.15 (t, *J* = 7.0 Hz, 2H), 7.10--7.14 (m, 2H), 7.57--7.61 (m, 2H), 9.96 (s, 1H), 12.44 (s, 1H). ^13^C NMR (175 MHz, DMSO-*d*~6~): δ 21.4, 21.8, 24.7, 29.0, 31.1, 34.8, 115.2 (d, *J* = 21.9 Hz), 120.7 (d, *J* = 7.7 Hz), 135.7 (d, *J* = 2.3 Hz), 157.8 (d, *J* = 238 Hz), 170.3. ^19^F NMR (376 MHz, DMSO-*d*~6~): δ −119.8. HRMS (ESI+) calcd for C~18~H~21~FN~3~O~2~S \[M + H\]^+^: 362.1333. Found: 362.1337 (Δ = −1.05 ppm).

### *N*-(1H-Benzo\[d\]imidazol-2-yl)-4-(4-oxo-3,4,5,6,7,8-hexahydroquinazolin-2-ylthio)butanamide (**3d**) {#sec4.6.3}

Off-white solid, 22% yield. Mp \> 230 °C. ^1^H NMR (700 MHz, DMSO-*d*~6~): δ 1.55--1.66 (m, 4H), 2.09 (m, 2H), 2.21--2.27 (m, 2H), 2.35--2.41 (m, 2H), 3.21 (t, *J* = 5.6 Hz, 2H), 3.27 (t, *J* = 5.6 Hz, 2H), 6.93 (t, *J* = 7.0 Hz, 1H), 7.11--7.22 (m, 2H), 7.38--7.48 (m, 3H), 12.45 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.4, 21.8, 23.7, 28.5, 31.0, 36.2, 113.6, 115.7, 116.4, 119.5, 124.1, 130.0, 143.4, 154.6, 156.5, 160.0, 162.4, 173.8. HRMS (ESI+) Calcd for C~19~H~22~N~5~O~2~S \[M + H\]^+^: 384.1489. Found: 384.1494 (Δ = −1.45 ppm).

### 4-(4-Oxo-3,4-dihydroquinazolin-2-ylthio)-*N*-phenylbutanamide (**4b**) {#sec4.6.4}

A mixture of 2-sulfhydrylquinazolin-4(3H)-one (**13**; 1.78 g, 10.0 mmol), methyl 4-bromobutanoate (2.72 g, 15.0 mmol), and K~2~CO~3~ (2.07 g, 15.0 mmol) in methanol (10 mL) and water (20 mL) was refluxed for 1 h. After being cooled to RT, 50 mL of water was added, and the reaction mixture was extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried over MgSO~4~, and concentrated *in vacuo* to give a crude product, which was purified by recrystallization from ethyl acetate/hexanes to give methyl 4-(4-oxo-3,4-dihydroquinazolin-2-ylthio)butanoate (2.24 g, 81% yield) as a white solid. Mp: 153--154 °C. ^1^H NMR (700 MHz, DMSO-*d*~6~): δ 1.96 (m, 2H), 2.45 (t, *J* = 7.0 Hz, 2H), 3.23 (t, *J* = 7.0 Hz, 2H), 3.58 (s, 3H), 7.39 (t, *J* = 7.0 Hz, 1H), 7.49 (d, *J* = 7.0 Hz, 1H), 7.73 (t, *J* = 7.0 Hz, 1H), 8.02 (d, *J* = 7.0 Hz, 1H), 12.55 (s, 1H). ^13^C NMR (175 MHz, DMSO-*d*~6~): δ 24.3, 28.9, 32.1, 51.4, 120.0, 125.6, 125.9, 126.0, 134.5, 148.3, 155.5, 161.3, 172.8. HRMS (ESI+) Calcd for C~13~H~15~N~2~O~3~S \[M + H\]^+^: 279.0798. Found: 279.0802 (Δ = −1.42 ppm).

A mixture of methyl 4-(4-oxo-3,4-dihydroquinazolin-2-ylthio)butanoate (1.39 g, 5.0 mmol) in DMSO (1 mL) and LiOH (aqueous, 1M, 10 mL) was stirred at RT for 2 h. To the reaction mixture was added 100 mL of water, and it was adjusted to pH 1. The resulting precipitate was collected on a filter and washed with water to give 4-(4-oxo-3,4-dihydroquinazolin-2-ylthio)butanoic acid (**14**; 1.14 g, 86% yield) as a white solid. Mp: 178--179 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.90--1.96 (m, 2H), 2.37 (t, *J* = 7.0 Hz, 2H), 3.24 (t, *J* = 7.0 Hz, 2H), 7.41 (t, *J* = 7.5 Hz, 1H), 7.52 (d, *J* = 7.5 Hz, 1H), 7.75 (t, *J* = 7.5 Hz, 1H), 8.02 (d, *J* = 7.5 Hz, 1H), 12.37 (s, 2H). ^13^C NMR (175 MHz, DMSO-*d*~6~): δ 24.3, 29.1, 32.5, 120.0, 125.6, 125.9, 126.0, 134.6, 148.3, 155.6, 161.3,173.9. HRMS (ESI+) Calcd for C~12~H~13~N~2~O~3~S \[M + H\]^+^: 265.0641. Found: 265.0646 (Δ = −1.56 ppm).

To a mixture of 4-(4-oxo-3,4-dihydroquinazolin-2-ylthio)butanoic acid (**14**; 132 mg, 0.50 mmol), aniline (186 mg, 2.0 mmol), and DMAP (67 mg, 0.55 mmol) in DMF (2 mL) was added EDC·HCl (144 mg, 0.75 mmol), and the mixture was stirred at RT for 18 h. To the reaction mixture was added 20 mL of water with stirring. The resulting precipitate was collected on a filter and recrystallized from 1,4-dioxane to give **4b** (61 mg, 36% yield) as a white solid. Mp: \> 230 °C. ^1^H NMR (700 MHz, DMSO-*d*~6~): δ 1.56--1.60 (m, 2H), 2.03 (t, *J* = 7.0 Hz, 2H), 2.84 (t, *J* = 7.0 Hz, 2H), 6.57 (t, *J* = 7.0 Hz, 1H), 6.83 (t, *J* = 7.0 Hz, 2H), 6.95 (t, *J* = 7.0 Hz, 1H), 7.01 (d, *J* = 8.4 Hz, 1H), 7.13 (d, *J* = 7.0 Hz, 2H), 7.25 (t, *J* = 7.0 Hz, 1H), 7.57 (d, *J* = 7.0 Hz, 1H), 9.48 (s, 1H), 12.12 (s, 1H). ^13^C NMR (175 MHz, DMSO-*d*~6~): δ 24.8, 29.2, 35.1, 119.0, 112.0, 123.0, 125.6, 126.0, 128.6, 134.5, 139.3, 148.4, 155.6, 161.2, 170.4. HRMS (ESI+) Calcd for C~18~H~18~N~3~O~2~S \[M + H\]^+^: 340.1114. Found: 340.1121 (Δ= −2.0 ppm).

In the same manner, compounds **4a**, **4c**, and **4d** were synthesized.

### *N*-(4-(Difluoromethoxy)phenyl)-4-(4-oxo-3,4-dihydroquinazolin-2-ylthio)butanamide (**4a**) {#sec4.7.1}

Off-white solid, 42% yield. Mp: 210--211 °C. ^1^H NMR (700 MHz, acetone-*d*~6~): δ 2.13--2.23 (m, 2H), 2.59 (t, *J* = 7.0 Hz, 2H), 3.41 (t, *J* = 7.0 Hz, 2H), 6.90 (t, *J* = 74.2 Hz, 1H), 7.11 (d, *J* = 8.4 Hz, 2H), 7.40 (t, *J* = 7.7 Hz, 1H), 7.49 (d, *J* = 7.7 Hz, 1H), 7.69 (m, 3H), 8.09 (d, J = 7.7 Hz, 1H), 9.25 (s, 1H), 11.22 (s, 1H). ^13^C NMR (175 MHz, DMSO-*d*~6~): δ 24.7, 29.2, 34.9, 116.5 (t, *J* = 256 Hz), 119.5, 120.0, 120.4, 125.6, 126.0, 134.5, 136.7, 146.1, 148.40, 155.6, 161.3, 170.4. ^19^F NMR (376 MHz, DMSO-*d*~6~): δ −81.4. HRMS (ESI+) Calcd for C~19~H~18~F~2~N~3~O~3~S \[M + H\]^+^: 406.1031. Found: 406.1033 (Δ = −0.44 ppm).

### *N*-(4-Fluorophenyl)-4-((4-oxo-3,4-dihydroquinazolin-2-yl)thio)butanamide (**4c**) {#sec4.7.2}

White solid, 46% yield. Mp: 216--217 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.20--2.05 (m, 2H), 2.47 (t, *J* = 7.0 Hz, 2H), 3.29 (t, *J* = 7.0 Hz, 2H), 7.09--7.14 (m, 2H), 7.38--7.41 (m, 1H), 7.45 (d, *J* = 8.0 Hz, 1H), 7.57--7.60 (m, 2H), 7.68--7.72 (m, 1H), 8.02 (dd, *J* = 8.0, 1.5 Hz, 1H), 9.97 (s, 1H), 12.56 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 24.7, 29.2, 34.9, 115.2 (d, *J* = 21.9 Hz), 112.0, 120.7 (d, *J* = 7.7 Hz), 125.6, 126.0, 126.0, 134.5, 135.7 (d, *J* = 2.4 Hz), 148.4, 155.5, 157.8 (d, *J* = 237.9 Hz), 161.2, 170.3. ^19^F NMR (376 MHz, DMSO-*d*~6~): δ −119.8. HRMS (ESI+) Calcd for C~18~H~17~FN~3~O~2~S \[M + H\]^+^ 358.1020. Found: 358.1027 (Δ = −1.99 ppm).

### *N*-(1H-Benzo\[d\]imidazol-2-yl)-4-(4-oxo-3,4-dihydroquinazolin-2-ylthio)butanamide (**4d**) {#sec4.7.3}

White solid, 25% yield. Mp \> 230 °C. ^1^H NMR (700 MHz, DMSO-*d*~6~): δ 2.05--2.09 (m, 2H), 2.61 (t, *J* = 7.0 Hz, 2H), 3.31 (t, *J* = 7.0 Hz, 2H), 7.07 (m, 2H), 7.33--7.50 (m, 4H), 7.58 (t, *J* = 7.0 Hz, 1H), 8.00 (d, *J* = 7.0 Hz, 1H), 11.52 (s, 1H), 12.06 (s, 1H), 12.57 (s, 1H). ^13^C NMR (175 MHz, DMSO-*d*~6~): δ 24.5, 29.0, 31.1, 111.5, 116.9, 120.0, 121.8, 125.5, 126.0, 132.5, 134.4, 140.5, 146.6, 148.4, 155.6, 161.3, 171.8. HRMS (ESI+) Calcd for C~19~H~17~N~5~O~2~S \[M + H\]^+^: 380.1176. Found: 380.1178 (Δ = −0.54 ppm).

### *N*-Hexyl-4-(4-oxo-3,4-dihydroquinazolin-2-ylthio)butanamide (**4e**) {#sec4.7.4}

To a mixture of 4-(4-oxo-3,4-dihydroquinazolin-2-ylthio)butanoic acid (**14**; 79 mg, 0.30 mmol) in 1,4-dioxane (2 mL) was added carbonyldiimidazole (CDI; 73 mg, 0.45 mmol), and the mixture was stirred at RT for 1 h. 1-Hexylamine (**5e**, 61 mg, 0.60 mmol) and DMF (5 mL) were added to the mixture and heated at 60 °C for 48 h. After being cooled to RT, 40 mL of water was added, and the reaction mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried over MgSO~4~, and concentrated *in vacuo* to give a yellow oil. Then, 20 mL of hexane was added to this oil with stirring to form a precipitate. The resulting precipitate was collected on a filter to give **4e** (46.7 mg, 45% yield) as a white solid. Mp: 168--169 °C. ^1^H NMR (700 MHz, DMSO-*d*~6~): δ 0.81 (t, *J* = 5.6 Hz, 3H), 1.20 (m, 6H), 1.35 (m, 2H), 1.92 (m, 2H), 2.22 (t, *J* = 7.0 Hz, 2H), 3.01 (m, 2H), 3.20 (t, *J* = 7.0 Hz, 2H), 7.40 (t, *J* = 7.7 Hz, 1H), 7.49 (d, *J* = 7.7 Hz, 1H), 7.73 (t, *J* = 7.7 Hz, 1H), 7.82 (s, 1H), 8.02 (d, *J* = 7.7 Hz, 1H), 12.55 (s, 1H). ^13^C NMR (175 MHz, DMSO-*d*~6~): δ 13.9, 22.1, 25.0, 26.1, 29.1, 29.3, 31.0, 34.2, 38.5, 120.0, 125.5, 125.9, 126.0, 134.5, 148.4, 155.7, 161.3, 171.0. HRMS (ESI+) Calcd for C~18~H~26~N~3~O~2~S \[M + H\]^+^: 348.1740. Found: 348.1742 (Δ = −0.54 ppm).

Cell Culture and Transfection {#sec4.8}
-----------------------------

COS-1 monkey epithelial, human fibrosarcoma HT-1080, and breast MCF-7 cancer cell lines were purchased from American Type Culture Collection (ATCC) and were maintained in Dulbecco's modified Eagle medium (DMEM; Invitrogen) containing 10% fetal calf serum under a 5% CO~2~ atmosphere. Transfection of plasmid DNA (human) into cells was achieved using polyethylenimine (Polysciences), and the transfected cells were incubated for 48 h at 37 °C followed by biochemical and biologic assays unless otherwise stated.

Two-Dimensional Dot Migration Assay {#sec4.9}
-----------------------------------

Transfected cells were mixed with an equal volume of neutralized type I collagen (3 mg mL^--1^) on ice. The cell--collagen mixture (1 μL of 1 × 10^7^ cell/mL) was then dotted onto a 96-well plate. After solidification of cell--collagen dots, the cell--collagen hemispheres were covered with 100 μL of complete media and incubated for 8--18 h (incubation time varies by cell type), followed by staining with DAPI nuclear dye and counting of the migrated cells using a Nikon Elements Basic Research Software analysis tools.^[@ref50]^

Co-immunoprecipitation {#sec4.10}
----------------------

Twenty-four hours following transfection, the conditioned medium in the absence of serum was collected from the transfected HT1080 cells. The cells were then lysed in RIPA buffer containing 10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, and a protease inhibitors mixture (Sigma). Both the conditioned medium and the cell lysates were incubated with specific antibodies overnight (18 h) at 4 °C. Antigen antibody complexes were precipitated with protein A-agarose beads followed by a brief centrifugation, washing, and then electrophoresis in a 10% SDS-polyacrylamide gel. Western blotting was then followed using a corresponding antibody as previously described.^[@ref12]^

Immunofluorescence {#sec4.11}
------------------

Cultured cells were fixed with 4% paraformaldehyde/phosphate-buffered saline (PBS) followed by blocking with 5% bovine serum albumin (BSA)/PBS. Both FAK and PAX were detected with an anti-p-FAK^Tyr 576/577^ and anti-p-PAX^Tyr118^ antibody followed by secondary antibodies conjugated with antirabbit Alexa 568 or Alexa 488, respectively (Invitrogen). For colocalization experiments, MMP-9 was detected with an anti-MMP-9 antibody followed by a secondary antibody conjugated with antirabbit Alexa 488, while α4 and β1 integrins were detected with an anti-α4 integrin and anti-β1 integrin, respectively, followed by a secondary antibody conjugated with antimouse Alexa 568. Nuclei were counterstained with DAPI (Invitrogen). Images were captured using a Zeiss LSM 510 META NLO Two-Photon Laser Scanning Confocal Microscope System (Central Microscopy Imaging Center, Stony Brook University).

Fluorogenic Assay of Enzyme Activity {#sec4.12}
------------------------------------

Mca-PLGL-Dpa-AR-NH~2~ fluorogenic peptide substrate (final concentration of 10 μM in DMSO) was incubated with the compounds and *p*-aminophenylmercuric acetate (APMA)-activated proMMP-9 for 30 min at 25 °C before detection. Fluorescence emission at 405 nm with excitation at 320 nm was measured in a fluorescent plate reader (Gemini EM; Molecular Devices).^[@ref51]^

Cell Viability {#sec4.13}
--------------

HT1080 cells were cultured in complete media with or without compound **3c**. Media and drugs were changed on a bidaily basis, and cell viability was monitored by MTT assay \[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide\] (Promega, Madison, WI). Each day, cells were exposed to MTT and incubated at 37 °C for 4 h. The reaction was stopped, and formazan crystals were solubilized; the resultant solution was subject to colorimetric spectrophotometry and read at a wavelength of 570 nm.^[@ref52]^

Chorioallantoic Membrane Angiogenesis and Invasion Assay {#sec4.14}
--------------------------------------------------------

The chorioallantoic membrane (CAM) assay was performed as previously described.^[@ref53]^ Fertilized white chicken eggs (SPF Premium, Charles River Laboratory, North Franklin, CT) were incubated at 37 °C in 70% humidity for 3 days. The embryos were then incubated *ex ovo* in a sterile Petri dish for 7 days. Gelatin sponges adsorbed with HT1080 cells treated with or without compound **3c** were implanted on the CAM surface, and neovasculature was counted on day 4 postimplantation.^[@ref54],[@ref55]^ For histochemical analysis of the chorioallantoic membrane, embryos were treated as for the angiogenesis assay, except at day 10 the embryos were inoculated with pretreated HT1080 cells mixed with a type IV collagen solution (3 mg mL^--1^). After a 7-day incubation, CAM segments containing the cell dot collagen mixture were isolated, formalin fixed, and sectioned by microtome into 6-μm sections after embedding in OCT. Sections were then stained with hematoxylin and counterstained with eosin.^[@ref56]^

proMMP-9 Protein Purification {#sec4.15}
-----------------------------

For purification of proMMP-2 and proMMP-9 protein, COS-1 cells stably expressing each respective MMP were incubated overnight in 10 mL of serum-free medium until 500 mL was collected for purification *via* a gelatin-sepharose column. Both proMMP-2 and proMMP-9 have three fibronectin repeats present in their gelatin binding domain, which allowed us to capture and collect the secreted protein present in the serum-free medium fraction. Protein was then eluted off the gelatin sepharose column using 5% DMSO and then dialyzed to remove any organic contaminants. A coomassie blue gel was then run to check the purity of the samples to ensure no protein contamination was present in the final solution. All methods were followed as previously described.^[@ref57]^

Fluorescence Spectroscopy {#sec4.16}
-------------------------

Binding of compound **3c** to proMMP-9 was assayed by observing the change of tryptophan emission upon binding. Purified recombinant proMMP-9 (0.5 μM) or MMP-9/MMP-2PEX (0.5 μM) was diluted in TNC buffer (50 mM Tris-HCl at pH 7.5, 150 nM NaCl, 10 mM CaCl~2~; pH 7.5) in the presence or absence of compound **3c**. As a control for protein stability and loss, an analogous buffer solution was added to the protein. The protein sample was excited at 280 nm, and emission scans were collected from 300 to 425 nm, using slit widths of 0.3 nm on a QM-4/200SE spectrofluorimeter with double excitation and emission monochromators. Between each titration, the protein/inhibitor mixture was gently stirred for 1 min at RT before collecting each reading. Three emission scans were collected and averaged at each concentration. The *K*~d~ was determined using the Prism software package (GraphPad V5) to fit the data to the equation Δ*F*/Δ*F*~Max~, in which Δ*F* is the nanometer shift for a given titration and Δ*F*~Max~ is the maximal nanometer shift observed overall.

Small Molecule DOCKing {#sec4.17}
----------------------

To DOCK the MMP-9 PEX domain inhibitors and predict the binding mode, the inhibitors were first created *via* the Advanced Chemistry Development Chemsketch software (ACD Laboratories, Toronto, Canada) in the MOL format. The molecules were then loaded into the program Avogadro to undergo energy minimization and were then saved as PDB format files. Once in PDB format, the molecules were individually loaded into the AutoDock Tools (The Scripps Research Institute, La Jolla, California) program and assigned charges, rotatable bonds, and a root. The molecules were saved as a pdbqt files and then used for DOCKing. The crystal structure of the PEX domain of MMP-9 was downloaded from rcsb.org (PDB code 1ITV). Chain B and all sulfate ions were deleted, followed by a brief energy minimization of the receptor *via* the AMBER force field. The parameters are as follows.

Steepest descent steps: 100

Steepest descent size (Angstroms): 0.01

Conjugate gradient steps: 30

Conjugate gradient step size (Ångstroms): 0.02

Force field: AMBER ff14SB (AM1-BCC)

The compounds docked underwent energy minimization *via* the Merck Molecular Force Field 94s (MMFF94s). DOCKing was performed *via* AutoDock Vina with the following parameters (untransformed coordinates of protein):

Box center (*x* axis) = −42.494

Box center (*y* axis) = −27.748

Box center (*z* axis) = 5.00

Box size (*x* axis) = 22

Box size (*y* axis) = 22

Box size (*z* axis) = 20

Exhaustiveness = 64

The results were loaded in UCSF Chimera (UCSF, San Francisco, California) and saved as JPEG images.

Statistical Analysis {#sec4.18}
--------------------

Data are expressed as the mean ± standard error of triplicates. Each experiment was repeated at least three times. The Student *t* test and analysis of variants (ANOVA) were used to assess differences with *P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001.
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